Updated Jul 16, 2026
Machatha Stephen is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $114K.
Stephen Machatha is the Chief Development Officer at Aldeyra Therapeutics, Inc., a biotechnology company focused on developing treatments for immune-mediated and metabolic diseases. He has been involved in the company's efforts to advance its product candidates, including Reproxalap for dry eye disease.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-08-11 | ALDX | Aldeyra Therapeutics, Inc. | S — Open-market sale | 22.1K | $5.15 | $114K |
Stephen Machatha is the Chief Development Officer at Aldeyra Therapeutics, Inc., a biotechnology company focused on developing treatments for immune-mediated and metabolic diseases. He has been involved in the company's efforts to advance its product candidates, including Reproxalap for dry eye disease.…
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($114K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Machatha Stephen profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.